Details for New Drug Application (NDA): 021571
✉ Email this page to a colleague
The generic ingredient in IQUIX is levofloxacin. There are thirty-one drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the levofloxacin profile page.
Summary for 021571
Tradename: | IQUIX |
Applicant: | Santen |
Ingredient: | levofloxacin |
Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 021571
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION/DROPS;OPHTHALMIC | Strength | 1.5% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Mar 1, 2004 | TE: | RLD: | Yes |
Expired US Patents for NDA 021571
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Santen | IQUIX | levofloxacin | SOLUTION/DROPS;OPHTHALMIC | 021571-001 | Mar 1, 2004 | ⤷ Subscribe | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription